GVAX for Patients With Pancreatic Cancer
Smitha Krishnamurthi, MD, associate professor of medicine, Case Western Reserve University, describes GVAX for patients with metastatic pancreatic adenocarcinoma.
Clinical Pearls
Smitha Krishnamurthi, MD, associate professor of medicine, Case Western Reserve University, describes GVAX for patients with metastatic pancreatic adenocarcinoma. A phase II study of the vaccine waspresented at the 2014 Gastrointestinal Cancers Symposium.
- GVAX is a whole cell vaccine made of pancreatic cancer cells expressing GM-CSF. GVAX is given with low-dose cyclophosphamide.
- Patients in the study were randomized to receive cyclophosphamide/GVAX followed by CRS-207 or just cyclophosphamide/GVAX. CRS-207 is a modified Listeria bacteria which expresses mesothelin.
- Patients in the cyclophosphamide/GVAX and CRS-207 arm experienced an overall survival benefit of about 2 months (6.1 versus 3.9 months).
Recent Videos
Related Content
Survivorship Care Promotes Evidence-Based Approaches for Quality of Life and Beyond
March 21st 2025Article
Frank J. Penedo, PhD, explains the challenges of survivorship care for patients with cancer and how he implements programs to support patients’ emotional, physical, and practical needs.
Read More
